Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89510 | 0.98 | ALDH1A1 (0.43) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL623994 | 0.94 | RET (0.40) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5201558 | 0.90 | OPRM1 (0.42) | RETMAP3K20RIPK3OPRM1 | |
| SCHEMBL14862636 | 0.81 | OPRM1 (0.37) | OPRM1 | |
| SCHEMBL23778354 | 0.79 | PDE4A (0.42) | MEN1KMT2ARETMAP3K20RIPK3 | |
| Hydrochloric Acid SCHEMBL8355569 | 0.79 | OPRM1 (0.39) | ALDH1A1RETMAP3K20RIPK3OPRM1 | |
| SCHEMBL19249603 | 0.79 | NPC1 (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL18768887 | 0.79 | NPC1 (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL181145 | 0.79 | NPC1 (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3644735 | 0.78 | HSD11B1 (0.42) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174292-A | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors | 修复治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9617473-B2 | Switch element comprising a liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-1165528-B1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-20040072840-A1 | Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | US | disclosed |
| US-6642233-B1 | Strong affinity and high selectivity for the human NK1 receptors of substance P. | SANOFI-SYNTHELABO (FR) | 2003-11-04 | — | — | US | disclosed |
| US-6506750-B1 | N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle. | SANOFI-SYNTHELABO (FR) | 2003-01-14 | — | — | US | disclosed |
| CN-1353698-A | Novel morpholine derivatives, method for production thereof and pharmaceutical preparations containing said derivatives | SANOFI SYNTHELABO (FR) | 2002-06-12 | — | — | CN | disclosed |
| CN-1345317-A | (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for production thereof and pharmaceutical compositions containing the same | SANOFI SYNTHELABO (FR) | 2002-04-17 | — | — | CN | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1150970-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000047572-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | ALDH1A1 2934/4885NPC1 2120/4885RAB9A 3895/4885 |
| US-20040072840-A1 | Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | TACR1, TACR2, KCNJ11 | ALDH1A1 345/4885NPC1 503/4885RAB9A 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.